These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 28276682

  • 1. Anticancer Platinum(IV) Prodrugs Containing Monoaminophosphonate Ester as a Targeting Group Inhibit Matrix Metalloproteinases and Reverse Multidrug Resistance.
    Huang X, Huang R, Gou S, Wang Z, Wang H.
    Bioconjug Chem; 2017 Apr 19; 28(4):1305-1323. PubMed ID: 28276682
    [Abstract] [Full Text] [Related]

  • 2. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L, Huang X, Huang R, Gou S, Wang Z, Wang H.
    Eur J Med Chem; 2018 Aug 05; 156():666-679. PubMed ID: 30031977
    [Abstract] [Full Text] [Related]

  • 3. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
    Huang X, Wang M, Wang C, Hu W, You Q, Yang Y, Yu C, Liao Z, Gou S, Wang H.
    Bioorg Chem; 2019 Nov 05; 92():103236. PubMed ID: 31494328
    [Abstract] [Full Text] [Related]

  • 4. Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance.
    Huang X, Huang R, Gou S, Wang Z, Liao Z, Wang H.
    Bioorg Med Chem; 2017 Sep 01; 25(17):4686-4700. PubMed ID: 28728896
    [Abstract] [Full Text] [Related]

  • 5. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
    Ratzon E, Najajreh Y, Salem R, Khamaisie H, Ruthardt M, Mahajna J.
    BMC Cancer; 2016 Feb 23; 16():140. PubMed ID: 26906901
    [Abstract] [Full Text] [Related]

  • 6. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F, Qin X, Xu G, Gou S, Jin X.
    Biochem Pharmacol; 2017 Jul 01; 135():50-68. PubMed ID: 28288821
    [Abstract] [Full Text] [Related]

  • 7. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
    Liu Z, Wang M, Wang H, Fang L, Gou S.
    Eur J Med Chem; 2020 May 15; 194():112269. PubMed ID: 32248002
    [Abstract] [Full Text] [Related]

  • 8. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 9. Naproxen platinum(iv) hybrids inhibiting cycloxygenases and matrix metalloproteinases and causing DNA damage: synthesis and biological evaluation as antitumor agents in vitro and in vivo.
    Chen Y, Wang Q, Li Z, Liu Z, Zhao Y, Zhang J, Liu M, Wang Z, Li D, Han J.
    Dalton Trans; 2020 Apr 28; 49(16):5192-5204. PubMed ID: 32236281
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L, Fregona D.
    Chem Biol Interact; 2004 Jun 30; 148(1-2):37-48. PubMed ID: 15223355
    [Abstract] [Full Text] [Related]

  • 11. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
    Chen H, Wang X, Gou S.
    J Inorg Biochem; 2019 Apr 30; 193():133-142. PubMed ID: 30731264
    [Abstract] [Full Text] [Related]

  • 12. Combination of 7-hydroxycoumarin in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action.
    Hua W, Zhao J, Hu W, Gou S.
    J Inorg Biochem; 2018 Sep 30; 186():17-23. PubMed ID: 29807243
    [Abstract] [Full Text] [Related]

  • 13. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI, Kim JH, Lee KT, Choi JH.
    Gynecol Oncol; 2011 Dec 30; 123(3):588-96. PubMed ID: 21945308
    [Abstract] [Full Text] [Related]

  • 14. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
    Xu Z, Hu W, Wang Z, Gou S.
    Eur J Med Chem; 2017 Dec 01; 141():211-220. PubMed ID: 29031068
    [Abstract] [Full Text] [Related]

  • 15. Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12.
    Sasanelli R, Boccarelli A, Giordano D, Laforgia M, Arnesano F, Natile G, Cardellicchio C, Capozzi MA, Coluccia M.
    J Med Chem; 2007 Jul 26; 50(15):3434-41. PubMed ID: 17583333
    [Abstract] [Full Text] [Related]

  • 16. Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance.
    Huang X, Li G, Li H, Zhong W, Jiang G, Cai J, Xiong Q, Wu C, Su K, Huang R, Xu S, Liu Z, Wang M, Wang H.
    J Med Chem; 2024 May 23; 67(10):8020-8042. PubMed ID: 38727048
    [Abstract] [Full Text] [Related]

  • 17. Dual-targeting antitumor hybrids derived from Pt(IV) species and millepachine analogues.
    Huang X, Hua S, Huang R, Liu Z, Gou S, Wang Z, Liao Z, Wang H.
    Eur J Med Chem; 2018 Mar 25; 148():1-25. PubMed ID: 29448138
    [Abstract] [Full Text] [Related]

  • 18. On the stability and biological behavior of cyclometallated Pt(IV) complexes with halido and aryl ligands in the axial positions.
    Escolà A, Crespo M, López C, Quirante J, Jayaraman A, Polat IH, Badía J, Baldomà L, Cascante M.
    Bioorg Med Chem; 2016 Nov 15; 24(22):5804-5815. PubMed ID: 27670096
    [Abstract] [Full Text] [Related]

  • 19. Platinum(II/IV) complexes containing ethylenediamine-N,N'-di-2/3-propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells.
    Kaluđerović GN, Mijatović SA, Zmejkovski BB, Bulatović MZ, Gómez-Ruiz S, Mojić MK, Steinborn D, Miljković DM, Schmidt H, Stošić-Grujičić SD, Sabo TJ, Maksimović-Ivanić DD.
    Metallomics; 2012 Aug 15; 4(9):979-87. PubMed ID: 22820831
    [Abstract] [Full Text] [Related]

  • 20. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
    Yu C, Ding B, Zhang X, Deng X, Deng K, Cheng Z, Xing B, Jin D, Ma P, Lin J.
    Biomaterials; 2018 Feb 15; 155():112-123. PubMed ID: 29175080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.